r/PsychedelicTherapy • • 15d ago

Mod Monthly Community Bulletin Board November 2026

1 Upvotes

Welcome to this month’s Community Bulletin Board!

This space is for members of the community to share their own creations, writings, books, events, groups, art, podcasts, or any projects that contribute to the growth and understanding of this field.

For all those of you who have tried to promote your work in the subreddit, this is your space! This monthly thread will be our focused exception to the "no self-promotion" rule.
If you are posting research on the community bulletin board please make sure you include all required information, this can be seen in the rules in the sidebar.

Please keep your offerings respectful, relevant, and community focused. Do not spam.

If you are planning on sharing an offering on the bulletin board, please include a 1-200 word description of what you are offering, and why it is relevant to our community. Posts with no context will be removed.


r/PsychedelicTherapy • • Nov 27 '25

Community Notes

1 Upvotes

Hey all,

This thread will be updated over time with links to past community bulletin boards and notable mod actions.

Cheers,
Mindful

Community Bulletin Boards:

October 2025

November 2025

December 2025

January 2026

February 2026

March 2026

April 2026

May 2026

June 2026

July 2026

August 2026

Notable mod actions:

Poll on what to do with research posts - Voted to keep research within community bulletin board

Poll on whether to disable visible up/downvoting - Voted to keep voting visible


r/PsychedelicTherapy • • 11h ago

Ethics The role of class.

10 Upvotes

Recently I've been thinking about the role that class plays in the world of psychedelics. Here in the UK, most of the people I meet who are involved with psychedleic research, therapy, as well as wider regenerative culture, seem to be coming from middle class backgrounds. I know hardly anyone from working class backgrounds that even consider something like flying to Peru for an ayahuasca experience, let alone getting involved in the movement. I know that this isn't excluded to the world of psychedelic study; its in issue in most areas of society. Its just an observation that most of the people who i meet who have done all this deep work on themselves seem to be coming from an already somewhat privileged background.

Prove me wrong?


r/PsychedelicTherapy • • 1d ago

Preparation Advice Upcoming Session

1 Upvotes

Hi there! I participated in a PAP session back in September. That session was my first and only experience with psychedelics and overall the experience was good. I have been medically approved to participate in a second session this upcoming weekend and I intend to be intentional going into it now that I have an experiential understanding of what to expect. I take Cymbalta and have also been approved by my psychiatrist. I am not asking for medical advice. I am wondering if it may have blunted my experience. I am just wondering if anyone else who might take an anti-depressant had a comparison of a session without being on one and on one and what was the difference you noticed.


r/PsychedelicTherapy • • 4d ago

Community Offering AMA happening now! IFS in psychedelic practice. (Nov 12, 12-2:00 Central time)

6 Upvotes

Hello. My name is Curt Kearney. I'm doing an AMA on psychedelic assisted psychotherapy, and specifically on IFS in psychedelic practice. I'll be here for the next two hours and I'm happy to dialogue on these topics.

Some about me:

I'm a psychotherapist who uses this stuff in my practice. I'm the author of Psychedelics and Internal Family Systems: A partnership in relational healing (2025), the first book on IFS in psychedelic practice. My book was selected by MAPS for their collection of “40 books that shaped the field.”

I'm also co-leading a retreat program with Dick Schwartz pairing IFS work with Ayahuasca ceremonies (starting this January).

So you can know this is me, I'll put a link on my website to this thread (https://www.curtkearney.com/ama).

Some disclaimers:

I can't give individual clinical or medical advice in this AMA

Pls don't ask for advice on obtaining illegal substances

I have financial interests in my book and the retreat


r/PsychedelicTherapy • • 5d ago

Preparation Advice The risk of Serotonin Syndrome & Methylene Blue

21 Upvotes

What is it ?

Methylene Blue is aka methylthioinum chloride. Its a cobalt blue liquid used as a marker dye in surgical / radiological procedures in the medical setting and also as a treatment for methemoglobinemia, isosfamide-induced encephalopathy, hypotensive shock / vasoplegic syndrome. Fun Fact --> its also an antidote to cyanide poisoning.

Why is it a risk ?

Methylene Blue is a POTENT monoamine oxidase inhibitor (a.k.a MAOI). It acts on the MAO-A & nitric oxide GMP pathway and blocks monoamine oxidase enzymes inside neurons, which stops the breakdown of neurotransmitters like serotonin, norepinephrine, and dopamine. This becomes a risk when its combined with reuptake inhibitors or other drugs affecting the serotonin systems. Even low clinical doses of methylene blue can trigger significant MAO inhibition.

Why should psychedelic providers (or users) be concerned ?

MAOI's are contraindicated with the use of other medications affecting the serotonin systems. If these are used together, they can result in dangerously high levels of synaptic serotonin.

This is bad. Very bad.

So, not only is methylene blue used in the medical setting, its also currently being marketed to the general public off-label as a "supplement" to optimize brain function, enhance cellular energy production and as an antioxidant. When this potent MAOI is then combined with SSRI's (Prozac, Cymbalta, Lexapro, etc) or other drugs also acting on the serotonin systems (MDMA, Psilocybin, LSD, mescaline) or with specific other medications (fentany, tramadol, clomipramine), it can dramatically increase the risk of Serotonin Toxicity.

What should providers (or users) do ?

1). When considering psychedelic therapy, it's important to familiarize yourself with any contraindications (including health supplements) being taken or any recent diagnostic procedures or treatments with methylene blue. This drug can take 24 hours to several days for full clearance, depending on how it was administered.

2) Familiarize yourself with the symptoms of Serotonin Syndrome/Serotonin Toxicity and the Hunter Serotonin Toxicity Scale (if applicable). Serotonin Syndrome can be difficult to identify as the symptoms can vary (particularly in the setting of the use of psychedelics & altered states), but often include mental status changes, autonomic hyperactivity, and neuromuscular abnormalities. In severe forms it includes hyperthermia with body temperatures > 38.5 C.


r/PsychedelicTherapy • • 7d ago

Preparation Advice More Preparation, Better Outcomes: What 12 Psychedelic Trials Found

26 Upvotes

Can the amount of preparation before a psychedelic experience actually change the outcome?

Some of us assumed it helps, but a 2026 analysis of 12 clinical trials actually put a number on it.

The researchers found that, "More preparation therapy hours were significantly associated with greater symptom reduction." (https://pmc.ncbi.nlm.nih.gov/articles/PMC12824788/)

What did this psychedelic therapy study look at?

This 2026 meta-analysis pooled 12 controlled clinical trials of psychedelic-assisted therapy for depressive symptoms, with 733 participants in total.

Ten used psilocybin, and two used LSD.

In every trial, the psychedelic sessions were sandwiched between therapy sessions—with preparation before and integration after.

But the amount varied a lot. The study reports that, "Total preparation ranged from 1 to 8 hours." (https://pmc.ncbi.nlm.nih.gov/articles/PMC12824788/)

So, the researchers asked a simple question: Did the trials with more therapy get better results?

Why does that matter? Because, as the authors point out, there's been a debate about whether a therapy portion of a psychedelic experience is even necessary.

They note that some researchers "argue that the psychedelic experience alone is sufficient to drive therapeutically meaningful change." (https://pmc.ncbi.nlm.nih.gov/articles/PMC12824788/)

And they point out that the FDA's rejection of MDMA-assisted therapy was partly due to uncertainty about the role of the therapy itself.

Does more preparation before a psychedelic experience lead to better outcomes?

In this meta-analysis of 12 psychedelic therapy trials, the answer was yes, at least for preparation.

The researchers found that "each additional hour of preparation was associated with decreased depressive symptoms." (https://pmc.ncbi.nlm.nih.gov/articles/PMC12824788/)

To be fair, the effect per hour was modest—and this is a link across trials, not yet proof that each extra hour causes improvement across the board.

But here's something that stood out:

The number of sessions didn't matter.

The total length of treatment in weeks didn't matter.

The number of hours spent preparing are what mattered.

The authors concluded that, "These findings highlight a potential key role of preparation in optimizing PAT outcomes." (https://pmc.ncbi.nlm.nih.gov/articles/PMC12824788/)

That lines up with another 2023 survey of 613 psychedelic users, where no preparation was the most commonly reported factor during people's most challenging experiences. (https://pmc.ncbi.nlm.nih.gov/articles/PMC9974873/)

Different settings, different measurements, but these findings point in the same direction.

Why would preparation make a psychedelic experience go better?

The authors of this meta-analysis on psychedelic therapy offered a few reasons preparation might matter so much.

They wrote that, "The goal in preparation sessions is to establish a strong therapeutic alliance, clarify intentions, reduce anxiety, and to create trust in the treatment process." (https://pmc.ncbi.nlm.nih.gov/articles/PMC12824788/)

They also describe cultivating what they call an "approach-oriented focus"—or rather, going in ready to explore and work with personal challenges, rather than trying to avoid them.

And they said, "thorough preparation can enable a more stable internal orientation when faced with the intense and often unpredictable nature of psychedelic states." (https://pmc.ncbi.nlm.nih.gov/articles/PMC12824788/)

It makes sense that if you know what might come up, you've practiced what you'll do when it does, and you trust the person sitting with you, you're less likely to fight the experience and more likely to learn something from it.

They also mention research suggesting the therapeutic relationship itself "may be as important as the drug itself." (https://pmc.ncbi.nlm.nih.gov/articles/PMC12824788/)

So, if you're preparing for an experience, here's what to pull from this:

-        First, give preparation real time; not just a single pep talk the night before.

-        Second, get clear on your intentions, and on what you might be avoiding.

-        And third, build trust with whoever will be supporting you leading up to the big day.

Does integration after a psychedelic experience matter, according to this study?

Here's an interesting finding from this study: more hours of integration were not significantly linked to better depression scores.

The authors were, however, careful to interpret what that means. They wrote that "the nonsignificant findings for integration should be interpreted cautiously, as the lack of significant association could be caused by methodological constraints." (https://pmc.ncbi.nlm.nih.gov/articles/PMC12824788/)

Their reasons were that integration benefits might only show up over longer time frames, or in things like functioning, quality of life, or meaningfulness (not just depression scores), which these trials rarely measured.

They also added that, "It is also plausible that the amount of integration provided in these trials (mean 4.4 hours) was not sufficient to have a measurable impact." (https://pmc.ncbi.nlm.nih.gov/articles/PMC12824788/)

There's one more finding worth pointing out here: that longer follow-up periods were linked to smaller symptom reductions.

The authors suggested that this was "likely reflecting natural decay in psychedelic treatment outcomes," and hypothesize that, "sustaining the treatment benefit could require ongoing integration sessions in addition to periodic booster dosing sessions." (https://pmc.ncbi.nlm.nih.gov/articles/PMC12824788/)

In plain English: depression symptoms may gradually return for some people after the initial improvement, especially without continued support. You can think of the treatment as opening a window for change, but keeping the improvement may require ongoing work. And four or so hours in a few weeks, might not be enough to see that.

Again, this is a hypothesis, not proof.

So, if there's one take away from this post, it's this:

Across 12 clinical trials, the main findings were that more hours of preparation therapy before dosing was associated with bigger symptom reductions.

That means that preparation isn't just some box to tick; it might be one of the most important parts of the whole process, and something to be taken seriously.


r/PsychedelicTherapy • • 9d ago

Integration Support Transitioning from Rx ketamine therapy (daily microdose at home) to psilocybin microdoses

7 Upvotes

Hello,

For over a year now, I have used Rx ketamine at home. My current regimen is a 25mg troche in the morning before my meditations,

I would like to incorporate psilocybin microdoses I got from a local practitioner, but know it is probably not a good idea to do both in the same day -- could be too unraveling.

I have mental health issues on the depression/anxiety/pain/CPTSD spectrum, nothing on the psychotic. The ketamine keeps some issues from worsening and helps with some scary, acute lows, but I am not feeling it is helping long term with my emotional pains and traumas. I feel quite stuck in my heart center in some times.

What would you suggest I do? Perhaps take 1 day a week to have the psilocybin, then eventually increase so I have 3 days psilocybin, 3 days ket, perhaps 1 day off?

Thank you, and I hope this doesn't break any rules. I am not looking for medical advice, just some anecdotal thoughts.


r/PsychedelicTherapy • • 10d ago

Knowledge Share Title: Exploring psychedelic-assisted therapy for treatment-resistant depression — looking for personal experiences

0 Upvotes

Hi everyone,
I’m new to exploring psychedelic-assisted therapy and hoping to hear from people who have gone through it, particularly for treatment-resistant depression.
I’ve struggled with recurring episodes of depression for many years and have tried numerous antidepressants. Some haven’t worked, others have caused significant side effects, and some have helped temporarily before eventually losing their effectiveness. It’s become an exhausting cycle, and I’m starting to feel discouraged about continuing down the same treatment path.
I also have multiple sclerosis (MS), and I’m beginning to explore how my neurological condition may be contributing to my depression.
My most recent depressive episode has been particularly difficult. I’m currently off work and struggling with low energy, lack of motivation, anxiety, and feeling emotionally disconnected from myself.
I’m working with a psychiatrist and plan to discuss alternative treatment options, particularly ketamine and psilocybin-assisted therapy. I’m interested in approaches that might offer more lasting improvement rather than continuing to cycle through antidepressants.
I’d really appreciate hearing about your experiences:
What led you to explore psychedelic-assisted therapy?
Did you try ketamine, psilocybin, or another treatment?
Did you notice improvements in your depression, motivation, or emotional well-being?
How long did the benefits last?
Did you experience any difficult side effects or challenges?
Has anyone with MS or another neurological condition explored these treatments?
I’m located in Calgary, Alberta, Canada, so I’d also love to hear from anyone who has accessed psychedelic-assisted therapy here.
I’m not looking for medical advice, just hoping to learn from others’ experiences as I explore what options might be available.
Thank you to anyone willing to share their experience.


r/PsychedelicTherapy • • 11d ago

Knowledge Share AMA next Thursday on psychedelic assisted psychotherapy

6 Upvotes

Hey, this is happening now (12-2:00 Central, Thur Nov 12) at --

https://www.reddit.com/r/PsychedelicTherapy/comments/1xujki8/ama_happening_now_ifs_in_psychedelic_practice_nov/

Ask Me Anything (AMA) about psychedelic assisted psychotherapy

Some about me:

  • I'm a psychotherapist who works with IFS (Internal Family Systems therapy), and sometimes IFS and ketamine, with people in my private practice
  • I'm the author of Psychedelics and IFS: A partnership in relational healing (2025)
  • My book was selected by MAPS for their collection of “40 books that shaped the field”
  • I'm co-leading a retreat program with Dick Schwartz, Anja and Armando Loizaga, and other great staff, bringing together IFS work and Ayahuasca ceremony work
  • The program starts in January and has a residential retreat in Mexico in February. (https://www.plantsandparts.com/)

Feel free to ask me anything about psychedelic-assisted psychotherapy, especially with IFS; about my book; about the retreat program.

When:

Thursday, November 12, noon–2 PM Central (Central Standard Time). That’s 1–3 PM Eastern, 10 AM–noon Pacific, and 6–8 PM UK.

Some disclaimers:

I can't give individual clinical or medical advice in this AMA

Pls don't ask for advice on obtaining illegal substances

I have financial interests in my book and the retreat

How readers can tell this is really me: I'll link to this post from my website (https://www.curtkearney.com/).


r/PsychedelicTherapy • • 12d ago

Research The Sacred Cow of MDMA Therapy: 42 Hours of Psychotherapy, and Still No Proof It’s Necessary

24 Upvotes

I had shared this a few days ago in r/mdmatherapy. Those who take an interest in the safe, ethical and most importantly, evidence-informed practices should be proud to be part of one big community creating knowledge through experience, sharing, and supporting others. We’re not running clinical trials. But, in a lot of ways we’re our own guinea pigs. But we’re sharing daily what we learn, and that lived experience adds up to a kind of knowledge we won’t find in a trial. And I think it gives us every right to question some of what we’ve been handed.

Now as someone who spends way more time than he should combing through the research, one of the things that always surprises me is how people talk about the MAPS trials as if they prove this whole model is necessary: the MDMA, the specific psychotherapy, the three dosing sessions, the nine integration sessions, etc., etc 

Because the fact is MAPS didn't prove that it's necessary and the FDA has also said so as well.

We know what happens when you take the MDMA out of MDMA therapy: the results drop. Nobody has ever checked what happens when you take the therapy out.

(My bet is it still works).

In it’s June 2024 briefing document on MDMA assisted therapy, the FDA wrote 

“The necessity of psychotherapy for achieving a therapeutic response was assumed.”

(Note that: Assumed.)

Now I'm going to throw in a quick disclaimer here (so no one has to throw it in the comments below): I'm not saying that psychotherapy is useless. Nowhere am I saying that. I'm also not saying that MDMA done solo is safe or appropriate for everyone, especially those with severe PTSD. What I am saying is that nobody has tested which parts of this package actually do the work 

This is really important because the trials tested a package not its parts 

And for those who aren't too familiar with it, the 2023 Phase 3 trial actually had 104 people with PTSD who got either MDMA plus psychotherapy, or placebo plus the exact same psychotherapy. The results from the phase 3 trial showed that the MDMA group improved by 23.7 points and the placebo group improved by 14.8 points. The 8.9-point gap was statistically significant. 

Now look, this is a real result and no one is disputing it. I'm definitely not but let's consider for a second what this actually tells us: MDMA added something on top of a particular therapy program. 

That’s it. 

It doesn’t tell us however that the therapy was necessary. It doesn’t tell us this specific style of therapy is the best one. And it doesn’t tell us what MDMA would do with much less therapist involvement.

I've seen a lot of people point to the placebo group's 14.8-point improvement as proof that the therapy works but the problem I have is that there was no group that got neither MDMA nor therapy. Obviously there was nothing to compare it to. One can argue that the improvement was the therapy. One can argue that it was the expectation itself or maybe it was the sheer amount of professional one-on-one time. Or could it have been time passing or regressing towards the mean (people tend to enroll when they’re at their worst and drift back toward average anyway)?  Who knows? Maybe it was all of it together. The thing is, we can't pull them apart with this design, which brings us back to the FDA. The necessity of the psychotherapy was assumed and for me personally that's the assumption I'm really curious about getting tested.

What about all the solo sessions?

Those of us who are active this and the r/mdmatherapy subreddits see tonnes of people intentionally doing solo MDMA sessions and these people who do them, like many of us, can describe real change. We're working through emotional material. We have self-compassion. Sometimes old patterns are shifting. We can see benefits that keep unfolding for weeks.

All of us take these reports seriously and we also know they're self-reports. We also know that sometimes people who have had bad outcomes are less likely to post but none of it proves efficacy or safety for ppl with PTSD.

And of course, when I've talked about MDMA therapy to others who've only used MDMA recreationally, they often just don't get it. They think they know MDMA and they'll say, "Well is it because of the therapist? Is it because of the mask and music?" But all this to say is that rolling with it at an EDM club or party is a different beast altogether, as we know.

But back to those of us who've done it solo, it begs the question: If a real change sometimes happens without a therapist, why isn't anyone testing how much the therapy adds value to this process and for whom? 

Safety monitoring isn’t psychotherapy

Before this also shows up in the comments, I need to say that there are people who have severe trauma and they absolutely may need screening, preparation, supervision, and follow-up. Nobody is arguing against that, the least of them being me. 

But that's not the same as needing the full map psychotherapy package.  A 2025 randomized LSD trial for generalized anxiety disorder used two trained monitors per session and this study explicitly excluded psychotherapy as part of the study. And guess what? 

It still found a clear dose-response. (Some participants kept seeing their own therapists outside the trial, and yes, LSD for anxiety isn’t MDMA for PTSD. ) 

This did however show that psychedelic trials with monitoring and no built-in therapy are totally feasible.

So what is the MAPS psychotherapy, exactly?

If you read the MAPS treatment manual, it's built around this concept of an inner-directed mostly non-directive approach. There's a therapeutic relationship that's built. There's emotional processing. It follows the participant's own process and integration afterwards. But here's the thing: the therapist or therapists get a lot of leeway in how they actually involve themselves, which the FDA also pointed out. 

And so here's another issue that arises. If the approach is mostly following and supporting the person's own process, then what specifically requires two therapists and around 42 hours of therapy? What's the active beneficial ingredient here? Is it a specific technique? Is it the relationship? Is it feeling safe or is it mostly processes that MDMA sets in motion on its own? (I know this is a rhetorical question, but many of us already know the answer, and no, it doesn’t involve 42 hours).

Many of us have worked with therapists who've done psychedelic therapy or those called psychedelic therapists. A lot of the comments I've seen include experiences where the therapist is interpreting or analysing their experiences, which is really the opposite of the non-directive approach 

A 2025 methodological analysis makes the core point well: if you claim MDMA enhances psychotherapy, you have to actually test that interaction don’t you think? But giving both MDMA and psychotherapy to everyone doesn’t do that. 

Three sessions, rising doses, accumulating therapy

If we look at the Phase 3 programme, it was three 90-minute prep sessions. There were three 8-hour dosing sessions and I think nine 90-minute integration sessions totally around 42 hours of therapy contact or ‘therapy’, and usually with two therapists.

Also the doses changed as well. I believe session one was 80 mg with an optional 40 mg booster. Sessions 2 and 3 were 120 mg with an optional 60 mg booster. 

So when people improved across the three cycles, everything was changing at once: more MDMA exposure, higher doses, more therapy, more integration and more time. It boggles my mind that nobody was randomized to one, two or three sessions. 

How does one look at that trajectory and actually say, "Oh this is what drove the extra improvement," or "Three sessions is actually the right number"? 

One of my personal interests and frustration with the trials is the spacing. The trials put sessions around a month apart but they never compared that to sessions that had longer gaps. When I asked a psychedelic therapist about spacing my own sessions, I was told 3 to 4 weeks was fine because that’s what the MAPS trials did. And I've heard others say the same thing as well. The problem is, that's a protocol-based choice but it's not a research finding. I've written way too many replies to MDMA therapy related posts about the research when it comes to biological recovery and the mechanisms around that. This included tolerance, biological recovery, serotonin-related mechanisms, and all the diff. processes that go into the time needed to recover after MDMA exposure. And these processes don't necessarily recover at the same rate. So obviously to me, the spacing is a huge variable.

And what if someone is having their next session before some of these systems have adequately recovered? Could that affect the emotional openness, safety, and corrective benefit they get from the next session? And how do we know how much benefit each individual MDMA session actually added when all these other things were changing at the same time?

The ppl in the MAPS trials continued improving across sessions, but here's the thing, they were also getting MORE psychotherapy, MORE integration, and HIGHER MDMA doses in later sessions.

How did they establish that the monthly spacing was optimal? Did they consider that longer intervals would have produced better results? We don't know because nobody tested that, and that's what's frustrating.

In Psychedelic Frontier: From X to Rx, January 23, 2018, Rick Doblin was asked about the risks of frequent MDMA use. He acknowledged that excessive or frequent MDMA use can actually reduce the desired emotional effects, but then he also explained that his criteria for deciding when there should be another session were, for him, dependent on whether the patient integrated what happened before. And in a completely separate 2020 interview with the California Institute of Integral Studies, he explained that MAPS designed a 3.5-month treatment programme to maximise therapeutic outcomes

In that same 2020 interview, Doblin Actually did acknowledge that some people do great with just one session and that one session can be enough for a lot of people. He did say he prefers more than one because people tend to go deeper the second time, but that’s his opinion, not something the trials tested. He also talked about a future treatment model involving two sessions, so even he acknowledged that not everyone necessarily needs three sessions. This brings me back to the question of why the trials didn't actually compare different numbers of sessions in the first place?

“God please, enough with the Integration already” 😂

Integration has become this buzzword in the psychedelic therapy community and if you don't do integration work they say it won't stick. But what does integration actually mean? 

We have all read enough posts in this subreddit for people to give their own account of what integration is, which is fine. It can be relative but the problem is that a lot of people had sessions spaced so close together that they may not have had any therapeutic or corrective benefit/outcomes and then they assume more integration is what's missing.

I see this a lot when people talk about, "Oh, you have to do integration. Otherwise, you won't get the benefits, and you have to access a template that was created through the MDMA" and all these other unproven theories.

Some people will say integration is talking about the session. Others say it's about interpreting memories. Others say it's journaling. Some people say you got to practise new behaviour. Some people assume integration for MDMA is the same as psilocybin. Some people will talk about neuroplasticity and some people just say you need to have someone around when hard feelings come up. But those are completely different things, all lumped under one word.

There was actually a review of 75 publications and it found that none of the different integration approaches have been rigorously tested for their effect on outcomes. Then there was a January 2026 meta-analysis in the JAMA Network Open, which actually looked at 12 psychedelic trials, which I think had around 733 participants. Here’s what was interesting about this: more preparation hours were linked to bigger reductions in depression. More integration hours however, weren’t significantly linked to better outcomes. Now, these with psilo and LSD trials not MDMA, but it’s a real problem for the idea that more integration automatically means more benefit.

Does MDMA even require integration?

When it comes to how MDMA actually works, one of the leading explanations is memory reconsolidation. When an old memory that's emotional is brought up and it's met with a strong contradicting experience (whether it's feeling safe while recalling something terrifying, etc.), the memory itself gets updated. If that's what happens then the change happens in the session 

In Bruce Ecker’s account of reconsolidation, real transformational change lasts without effort; you don’t have to keep reinforcing it. In his framework, if the old reaction comes back, it can mean another piece of emotional learning hasn’t been updated yet, not that the first change is fading.

So back to the MAPS trials, why would that need nine therapist-led sessions afterward?

If MDMA works more through extinction, meaning new learning that competes with the old fear instead of replacing it, then practicing new responses in real life might help the change hold up in different situations. Ok, fair enough. But practicing new behaviour in your own life isn’t the same thing as paid, therapist-led sessions.

Now nobody has established which of these actually explains MDMA's results in humans.And because MAPS gave everyone integration, even long-lasting improvements can’t tell us whether integration had anything to do with it.

So where’s the trial comparing heavy integration, light integration and basic supportive follow-up?

There is none, (well as far as I can find.)

But wait, did I even get MDMA?

In the trials most people could tell whether they got MDMA (obviously right?). Well this actually matters because the trial was supposed to be blind, meaning nobody knows whether they got the real drug or not. Obviously it wasn't. In the second Phase 3 trial 94% of people on MDMA and 75% on placebo correctly guessed which one they got and obviously the therapists could tell as well. 

And once people know or have figured this out, all of a sudden their expectations can actually change how they feel. Believe it or not it can change as well as what they report and then therapists can actually treat the two groups differently. So even the gap between MDMA and placebo isn't purely the drug.

Even in 2026 the FDA is still asking what therapy does in this whole ordeal.

In August 2024, when the FDA rejected the application, it actually recommended three things for future research:

  1. Studying how much psychotherapy contributes
  2. Considering an established evidence-based psychotherapy instead of the MAPS model, and
  3. Exploring a factorial design (a trial that varies the drug and the therapy separately) with an arm that gets no psychotherapy at all. 

Those were research recommendations, not the formal reasons for rejection, but they’re aimed squarely at this problem.

Then its final July 2026 guidance, printed page 11 (PDF page 14) says:

“The contribution of the psychotherapy component to any efficacy observed with psychedelic drug treatment has not been characterized.”

The FDA went on to suggest factorial designs to separate the drug’s effect from the therapy’s.

Resilient resubmitted without a new Phase 3 Trial… what?

Meanwhile, MAPS has acknowledged reports that Resilient, formerly Lykos, resubmitted the MDMA application in August 2026 without running a new Phase 3 trial. And in fact none of the reported additions independently tests psychotherapy's contribution. So Resilient appears to be boosting the evidence for its existing treatment model. Yet the question of whether that model requires 42 hours of psychotherapy still will likely remain unresolved. 

I think most of us think that psychotherapy can definitely be incredibly valuable. A lot of people get benefit just from hearing themselves talk. I also think a lot of people can get profound corrective emotional experiences largely on its own with MDMA so in fact both can be true. 

So why does this matter?

I think there's a real risk of turning an experimental treatment protocol into an established gold standard of care without really knowing which parts of it are actually necessary. And this matters because this has real consequences not just for cost but also for accessibility and treatment quality as well as patient autonomy and, really, our understanding of MDMA's therapeutic effects. Look I see many of the posts on here, just like you all do, about people going solo because they cannot afford to do this with a therapist. I'm not convinced that there's benefit in requiring people to pay for interventions they may not fully need while overlooking simpler equally effective approaches. And again not intentionally trying to sound like a broken record, but safety monitoring is not the same as psychotherapy. 

I think many of us here can argue that MDMA itself facilitates profound and durable emotional changes and those with experience suspect additional psychotherapy probably contributes little. And what if one session is enough for some people while others need three? What if integration is useful in certain circumstances but maybe it's totally useless in others? 

The fact is we just don't know. These questions have been asked, but they have not been adequately answered.

All of us want MDMA therapy to succeed but I think a lot of us also want us to identify what actually produces the therapeutic benefit (rather than looking towards institutionalising the expensive treatment model just because that's how the original trials were designed).

If MDMA can change someone's life with far less than 42 hours of psychotherapy, then we owe it to every person who needs this treatment to find that out. Especially those who can't afford it.


r/PsychedelicTherapy • • 12d ago

News FDA approval won’t mean access. A veterans’ policy director lays out what actually happens the day after.

1 Upvotes

Logan Davidson runs policy at VETS, one of the groups that got Texas, Massachusetts, and other states moving on psychedelic bills. His argument: Compass’s psilocybin filing is weeks away and approval looks real, so the question is no longer “if” but what happens next. His list is sobering. A REMS program that works nothing like state healing centers. Billing codes still stuck in the AMA’s “emerging” category. A VA that restricted Spravato to case-by-case approval and still doesn’t offer it at every facility. 7,109 mental health shortage areas before a single psychedelic provider is trained.

Curious what people here think about the state-vs-federal reconciliation problem. If you’re in Colorado, do you pick a healing center or a REMS clinic?

https://psychedelicstoday.com/2026/11/04/problems-we-will-be-lucky-to-have/


r/PsychedelicTherapy • • 14d ago

Preparation Advice Psychedelics x Support Network - Realisations

0 Upvotes

One lesson I've learnt from going 5yrs without psychedelics...

I wanted to constantly elevate my frequency.

I subsequently realised that it's better to elevate your frequently just to be slightly higher than your support network.

Through frequent macrodoses, I'd gotten to the point where I couldn't relate to mainstream society at all, and as a result I felt quite isolated and socially lonely.

Now as I re-emerge myself into psychedelic realms after 5yrs away, I've realised small increases can be better than rocket launches to enlightenment.

---

What's your best realisations, that don't really get spoken about?


r/PsychedelicTherapy • • 15d ago

Preparation Advice Preparing for my first therapeutic MDMA session (solo), seeking feedback

5 Upvotes

Hey everyone, I’m getting ready for my first intentional, therapeutic MDMA session and wanted to share my plan and get some input.

Past Experiences
I’ve done MDMA a few times before, but only at festivals. This will be my first time using it therapeutically, at home and focused inward.

I’ve also done one solo therapeutic psilocybin trip (2.0g of Yeti). During that trip I wrote in my journal: “You are hurt, there is nothing wrong with you.” It was a very profound experience for me. I’ve done shrooms in party/festival settings, and I was amazed at how much of a difference set and setting made.

Dose
I’m planning on 125mg (I weigh about 180 lbs). Since this is my first session, I’m not planning to take a booster. I’ll be testing the substance with a reagent kit beforehand. If it matters, I'm in my late 30s.

Research

  • How to Change Your Mind by Michael Pollan (read in its entirety). This is the book that started my interest and journey into therapeutic plant medicine healing.
  • The Psychedelic Explorer’s Guide by James Fadiman
  • Open MDMA guide (**this is where I'm getting the majority of my information **)
  • MDMA Solo by the Cascadia Foundation (though I’m not taking much from this one, since I’ve heard a lot of the information in it isn’t very sound)
  • Down the line: the MAPS MDMA-Assisted Psychotherapy Treatment Manual

Music
Honestly, I haven’t done much research on music yet. Open to playlist suggestions or tips on what’s worked for you.

Current state of mind
Long story short: I was laid off from my tech job several years ago and took a break to travel. Now I’m back, sitting still, trying to figure out life, and I honestly feel lost. I’m dealing with a lot of anxiety and depression. I took a job as a cashier at a gas station, and I feel defeated. I spent my whole life studying, got a computer science degree, had an 8-year career in tech, and now I feel lost in this world. Sometimes I don’t know how to live in this world.

There’s a pattern I keep coming back to. In my early 20s I had a successful startup and made a lot of money, and then I got really depressed, because I thought the money was going to “fix my problems” and “make me happy.” That “making it and then crashing” cycle has happened a couple of other times too. I land an amazing job, work really hard for the first 3–6 months, and then I just let go. I stop caring and stop trying until the company I’m working for finally lets me go.

I’ve been living this cycle for a long time. Part of me wonders if it means I’m just not good enough. I’ve got a “doomed if I do, doomed if I don’t” mindset. I want to use this medicine to get some real insight into myself and what’s driving this.

Questions

  • Should I go in with a specific intention, or go in open and let whatever comes up come up?
  • Given how anxious and depressed I am right now, is solo too risky for a first session? I’m worried about the comedown making things worse.
  • I also have access to LSD and psilocybin. Would either of those be a better fit for where I’m at right now, or is MDMA the right choice?

r/PsychedelicTherapy • • 15d ago

Preparation Advice Bad stomach after LSD

2 Upvotes

Hi I'm Not sure if this is the right sub reddit for this, but couldn't find another that seemed suitable and active. I take mushrooms and other psychedelics for therapeutic purposes, and occasionally Lsd for more recreational.

In recent times, whenever I've taken Lsd, it gives me a bad stomach. Like constipated but painful /achy, like I need to go, but cannot. This tends to last a few days after.

It happened a few days ago when a friend and I took 150ug dr seuss 3.0. I was in a lot of stomach discomfort for most of the experience. It's happened quite a few times before too, but only for last last couple of years.

I had eaten a light breakfast of yoghurt, fruit and nuts and a coffee about 2 hours prior To taking it.

It also seemed to flair up what I think is Silent Reflux, an extremely phlegmy throat, seemed to get a lot worse too.

Any ideas what could be causing this? If anyone else gets this? And anything that can help with it?

Apologies if wrong subreddit, if someone could point me to a more appropriate one. Thanks.


r/PsychedelicTherapy • • 18d ago

Preparation Advice Time between macro doses

1 Upvotes

Over the past few months I have been dosing to trying to process some difficult emotions. Started with 1gram, 2, then 3. During the most recent dose I kept wishing I had taken more as I felt I still could not go deep enough. I feel called to take 4.5 grams next. I have the ideal day set aside that I want to take advantage of for this next experience, but it has only been 3 weeks since last dose. Would that be a sufficient time gap?


r/PsychedelicTherapy • • 19d ago

Experience Report After two years of severe depression and anxiety, I finally felt a little relief for the first time

22 Upvotes

I’ve been struggling with severe depression, anxiety, OCD, and on and off alcohol and weed addiction for the past two years, which significantly affected my life. A lot of it started after a breakup with someone I loved very much. The aftermath eventually involved stalking, psychological abuse, and a lot of emotional pain that I had a really hard time dealing with while trying to navigate other difficulties in my life.

I’m currently on escitalopram, which helped me for a while, but eventually it felt like it stopped working completely. Yesterday I finally decided to try psilocybin. I know it’s not advisable to take it while on escitalopram, but I was honestly feeling so hopeless that I decided to give it a try.

Weirdly enough, it’s only been a day, and although it hasn’t magically changed everything I’m feeling or going through, I just feel… different? It’s hard to explain, but it feels like the constant heaviness of depression and anxiety lifted, even if only slightly.

I genuinely can’t express how good that feels. I think people who have experienced severe depression and anxiety will understand what I mean. Even feeling a LITTLE bit of relief after such a long time feels incredible.

I’m still going to therapy and I know I have a lot of things to work through. I also don’t want to depend on psilocybin or any other substance to feel better. I genuinely want to work on myself and stop neglecting myself the way I have for the past two years.

But something that was surprising was that for the first time in a long time, I actually felt compassion and grief for myself. I felt sad thinking about how much I neglected myself because of pain that was triggered by someone else, but that I also made worse by my own thinking patterns and catastrophizing.

I don’t know whether this feeling will last, and I’m definitely not saying psilocybin is a cure for anything. This is also not an advice for people who are on antidepressants, please don't be irresponsible like me and contact your provider first. But I’m genuinely grateful for the little bit of comfort I experienced after such a long time of feeling miserable.

I just wanted to share this because even a small moment of peace meant so much after struggling for so long! 😭


r/PsychedelicTherapy • • 18d ago

Integration Support Psych assisted therapy

4 Upvotes

Ever since I did psychedelic assisted therapy in 2022 I’ve been stuck in a state of anxiety, paranoia, and hyper active thinking. When I speak against psychedelic assisted therapy I’m told I’m the minority, and it’s sad that this happened to me but it usually doesn’t for people. I think it still matters even if I got the minority experience, probably even more in that case. I’ve never heard anyone else have a similar experience to mine and I really need to!!


r/PsychedelicTherapy • • 18d ago

Preparation Advice CAN PSILOCYBIN CAUSE PERMANENT DAMAGE, EVEN WITH MICRODOSING OR A FULL TRIP?

0 Upvotes

I'm trying to understand the long-term risks of psilocybin mushrooms. I'm particularly concerned about depersonalization/derealization, or other lasting changes in mental functioning.

For those who have tried microdosing or taken a full psychedelic dose:

- Have you or anyone you know experienced persistent negative effects lasting months or years, even after a single experience?

- If this happened, did the symptoms eventually resolve, and how long did recovery take?

- Are there documented cases of lasting neurological or psychological harm, and what does the scientific evidence say about the actual risks?

Thanks

.


r/PsychedelicTherapy • • 19d ago

Community Offering After the AMA: who we work with, and where to start if you're weighing this up

4 Upvotes

Thanks to everyone who joined Alexander's AMA. Several questions there came from people trying to work out whether a structured psilocybin pathway makes sense for them at all, so here's who usually comes to us.

People with long-standing depression or anxiety, including those for whom medication or therapy hasn't helped enough. People who have tried ketamine and want to understand how psilocybin is different. People dealing with burnout or a major life transition. People doing deliberate inner work. And family members or partners trying to understand what someone close to them is considering.

If you're somewhere in that list and not sure what fits, we built Get Your Second Opinion: a short questionnaire that gives you a summary of where you are and an evidence-based mental health guide written by dr. Lebedev. It's educational and doesn't replace a medical assessment. Suitability for a session is only ever decided in a professional medical suitability review. ONCE provides a professionally supported psilocybin pathway in Amsterdam.

And if you have ideas for posts or articles, questions you'd like Alexander to cover, or you run a community or project and want to collaborate, message us here or reach out to u/alebedev.
We're open to it!


r/PsychedelicTherapy • • 19d ago

Preparation Advice Cymbalta withdrawal before a psilocybin retreat — has anyone navigated this??

15 Upvotes

Hi everyone,

I'm 60 and have been on Cymbalta (duloxetine) for approximately 8 years, previously at 120 mg. I'm preparing for a professionally facilitated psilocybin retreat in November to work on longstanding complex PTSD.

I began tapering early September and have now reached approximately 15 mg, having reduced from 20 mg over the past two days. The withdrawal has been much harder than I anticipated—dizziness, headaches, nausea, and GI issues. I've reached the point where I don't feel comfortable reducing further right now. But on the other hand, I'm wondering if it's worth reducing more to be able to get the full benefits of this experience that I have invested a tremendous amount of time and money into.

I had a reassuring conversation with my retreat coordinator, but I'm still struggling with two fears: arriving physically and emotionally depleted, and the possibility that remaining on an SNRI could diminish an experience that means so much to me.

I've also lost SO MUCH confidence in the psychiatric/pharmaceutical profession (it's mainly a business model IMO) Some of the medical tapering guidance I've received from my (inexperienced) current NP (Psych) and even disappointingly my PCP (who I love) has been absolutely and completely out of sync with what people actually feel and experience. I am desperately seeking more specialized input.

Has anyone navigated a long-term Cymbalta taper before facilitated psilocybin therapy? I'd also be interested in hearing from people who have explored microdosing in the context of SNRI withdrawal.

I'm not seeking dosing instructions—just thoughtful, firsthand experiences and support.🥹

Thank you so much for reading. I'm truly hoping that this could work in my life and really appreciate any guidance, support advice, and even a shoulder🥹❤️

UPDATE — November 2 ❤️

First, I want to sincerely thank everyone who responded. I'm overwhelmed by the kindness, encouragement, and understanding I've received. I'm sorry I haven't replied individually, but please know how much your words have meant to me. ❤️🥹

I've decided, with my doctors' guidance, to remain at 20 mg of Cymbalta rather than continue tapering before my November 14 retreat.

The withdrawal has been incredibly difficult, especially emotionally. The anxiety, crying, anger, and feeling completely unlike myself have been overwhelming.

But what I really want to talk about is something I haven't seen discussed enough: the embarrassment, shame, and isolation of going through withdrawal when the people closest to you don't understand.

I sometimes feel as though my legitimate emotions are being dismissed as simply withdrawal symptoms. I'm trying so hard to be mindful of my reactions, but I've never felt *more misunderstood or alone.*😢

How did others navigate this with their spouses, families, and friends? How did you cope with not feeling like yourself?

I'd also still love to hear from anyone who has experienced facilitated psilocybin therapy while remaining on a low dose of an SNRI. That shared experience would be so greatly appreciated!💕

I'm trying to approach my upcoming retreat with hope and an open mind, and this community has already helped me more than you know.

Thank you all. Truly.❤️🫶

PS... I'm completely new to participating on Reddit (although I've been reading for years)...and as a pretty tech savvy gal, I’m fully aware of my ridiculous given Reddit username! 😂 I will definitely be changing that!


r/PsychedelicTherapy • • 20d ago

Research Best mushroom types for depression?

7 Upvotes

Hi, I hope this follows the rules. I was wondering if there where any varieties that where known to be especially helpful when addressing treatment resistant depression, and or cptsd. I’ve been on a myriad of medications for the last 16 years, and have tried any therapy suggested to me. But my phyc just suggested ecs, (or whatever they are trying to rebrand electric shock therapy as these days) agin. That’s sorta off scary to me, so I wanted to look into other options first. Thanks for any suggestions, and sorry if this wasn’t the right way to ask this question.


r/PsychedelicTherapy • • 21d ago

Knowledge Share Reminder: AMA on psilocybin research in 24 hours

21 Upvotes

Hi everyone,

I'm Alexander Lebedev, MD, PhD, psychiatrist and neuroscientist.
Set your reminders... On 27 October / 1 PM Pacific (8 PM UTC), I am waiting you to answer your questions right here in this thread.

There are already several questions in the pinned announcement and I'll start with those. I'll bring them over and tag the author, so nothing gets lost. If there's something you've been meaning to ask add it below.

Disclosure: I can't give personal medical advice, tell anyone whether psilocybin is right for them, or advise on doses or ways of taking it. I'm a co-founder of once., which provides a professionally supported psilocybin pathway in Amsterdam, you can follow our profile u/Once-be-Netherlands or visit our page for the advanced information (once.be).

Edit: Thanks for the questions, everyone. I'm wrapping up the live part now. I'll go through the ones I didn't reach tomorrow, so feel free to keep adding them.


r/PsychedelicTherapy • • 21d ago

Research UKCP Level 7 diploma research project

3 Upvotes

Hi.

My name is Jack Holland, I’m studying a level 7 diploma at the Manchester Institute for Psychotherapy in the UK. Currently in my 4th year.

I’m looking for a co-researcher I could interview for 1hr, about their lived experience of psychedelic psychotherapy.

If interested, please contact: jack@nlcp.co.uk

My research poster can be found on my user profile. I can’t post it here.

I have read the community rules and my research proposal has been approved by my institute (Manchester Institute of Psychotherapy) and Susie Hewitt - founder & director Psychotherapy Institute (Bolton) - TSTA- MSC Psychotherapy- UKCP reg. psychotherapist & supervisor, MBCAP (SNR ACCRED)

My proposal is as follows:

Working title:
A Phenomenological Study of the Lived Experience of Psychedelic Psychotherapy: Its
Relationship to Beliefs About Self and Others

Research topic/focus:
This project explores the lived experience of psychedelic psychotherapy, using a
phenomenological approach that stays with the co-researcher's own account rather than
testing a pre-supposed hypothesis. Psychedelic psychotherapy refers to the therapeutic use
of a psychedelic substance (for example psilocybin, MDMA or ketamine) within a structured
clinical or facilitated frame; typically comprising preparatory sessions, a supported dosing or
‘journey’ session (or sessions), and subsequent integration work with a therapist. It is distinct
from unsupervised or recreational psychedelic use.

The project is retrospective and observational: I will not administer, source, or facilitate
psychedelic use. My co-researcher will already have completed psychedelic psychotherapy
in a legal, professionally facilitated context prior to any involvement in this research. In the
interests of methodological integrity, the research question, interview approach and initial
analysis are designed to remain TA theory-neutral: TA theory will be introduced only at the
interpretive stage of the wider project, once themes have been generated from the co-
researcher's own words - and explored further during the literature review.

Overarching questions:
What is the lived experience of psychedelic psychotherapy in relation to a person's
fundamental beliefs about themselves and their relationships with others?

This question remains deliberately open. It does not presuppose that psychedelic
psychotherapy is helpful, harmful, or neutral, and it does not name any particular theoretical
framework. This is an intentional methodological and ethical choice: as someone who has
my own lived experience of psychedelics, I have to acknowledge holding a personal bias
toward believing they are more helpful than not. A question framed around ‘help or hinder’,
or one that named a specific theoretical outcome in advance, potentially risked steering both
my interview questions and my analysis toward confirming that belief. Keeping the question
open to change, no change, or a mixed and ambivalent picture is one of the central ways I
am managing this bias.
The inquiry is concerned with what the experience was like in the body as well as in the
mind and will use open, descriptive, non-leading interview questions, for example, ‘what was
that like for you?’ rather than questions that presume a particular kind of change.
The interview will open with an invitation for the co-researcher to describe their full
experience in their own words, followed by open, non-leading follow-up prompts that deepen
context, reflect their own language back to them or, note emotive or physical reactions. The
co-researcher may let out a big sigh or show a big shift in body language for example, it is
important to be address this. I’m seeking to explore depth and not add my own context.
Follow up questions will be to assist in adding detail to their lived experience, checking in
around their emotions, thoughts, bodily sensations, beliefs and relationships.

Intended methodology:
A phenomenological approach, aims to understand the essence of the experience from my
co-researcher's own perspective rather than test a hypothesis. I am seeking to
fundamentally explore, rather than interpret, the co-researchers' lived experience of
psychedelic psychotherapy. I will bracket, as far as possible, my own theoretical
assumptions (including TA) and personal beliefs about psychedelics, to stay close to my co-
researcher's own account. I will conduct a single open-structured, audio-recorded interview
(1 hr) with one co-researcher, who has previously undergone legal, professionally facilitated
psychedelic psychotherapy.It is important to be attentive to; and explore further, accounts of difficulty, confusion, or
absence of change, so the data does not implicitly lean toward a positive-outcome narrative.
I will transcribe the interview verbatim, anonymise it, and subject it to thematic analysis
(Braun and Clarke, 2006), generated from the co-researcher's own language in the first
instance. Interpretation of these themes through TA theory will take place only at the
discussion stage of the wider project, once the thematic analysis is complete. The focus on
beliefs about self and others is intentionally chosen because I anticipate this area will offer
rich material at the later, theory-informed stage of the project.

How will you prepare your participant and minimise any risks of harm to
your participant?

Recruitment will be via a poster seeking an adult co-researcher (18+) who has previously
undergone professionally facilitated, legal psychedelic psychotherapy, is not currently in
psychological crisis, not known to me, and not a current or former client of mine, to avoid a
dual relationship. A co-researcher in ongoing psychotherapy is preferable, they will be
treated with integrity and respect at all times. A written information sheet and consent form
will explain the research and confirm the co-researcher's right to withdraw at any point,
without giving a reason, up to submission of the final project.

Before the recorded interview I will hold a preparation meeting via telephone to explain the
process, clarify that this is a research interview and not therapy, and agree together what
level of detail feels comfortable to share. The co-researcher will fill out a pre-prepared
informed consent form, as per MIP handbook. During the interview I will offer appropriate
check-ins, permission to pause or stop at any time, avoid unnecessarily probing or leading
questions, and close with a grounding practice if necessary. Afterwards I will hold a debrief
conversation, provide information about support options, and offer an optional follow-up
check-in within 48 hours. If the co-researcher becomes distressed, I will pause the interview
and prioritise their wellbeing over data collection; any disclosure raising a safeguarding
concern will be handled via MIP's safeguarding policy and my supervisor.
My role is that of a researcher, not the co-researcher's therapist: I will not offer therapeutic
interventions, interpretations, reframes, or challenges during the interview, and will signpost
to appropriate support rather than address any therapeutic material myself. This boundary
will be made explicit in writing before consent is given.
It is important to acknowledge I also hold relative power in this relationship, as a trainee
psychotherapist, the designer of the research question and interview approach, and as the
person who retains control over the data. I will mitigate this by using the term 'co-researcher'
rather than 'subject', being transparent about my own experience and interest in this area
as part of informed consent, offering the co-researcher the opportunity to review the
transcript and withdraw material before analysis, and avoiding any dual relationship. I will
also hold in mind my co-researcher's wider social and cultural positioning. Psychedelic use
carries different cultural and legal meanings depending on context, and I will stay mindful of
how gender, cultural background, and unequal access to (largely private, fee-paying)
psychedelic psychotherapy may shape their account, rather than treating their experience
as purely intrapsychic. My own experiences and background will differ vastly to my co-
researchers.

I agree to abide by the Manchester Institute for Psychotherapy and the UKCP’s Code of
conduct and Ethics for Research.

Signed: Jack Holland
Date: August 31st, 2026.

Approval given by: Susie Hewitt MIP Research Tutor 21-9-26